These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 28833619)
1. Cost-effective options for the prevention and management of gastrointestinal and liver disease in the Asia-Pacific region. Roberts-Thomson IC; Lung T J Gastroenterol Hepatol; 2018 Jan; 33(1):121-127. PubMed ID: 28833619 [TBL] [Abstract][Full Text] [Related]
2. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. Mohamed R; Desmond P; Suh DJ; Amarapurkar D; Gane E; Guangbi Y; Hou JL; Jafri W; Lai CL; Lee CH; Lee SD; Lim SG; Guan R; Phiet PH; Piratvisuth T; Sollano J; Wu JC J Gastroenterol Hepatol; 2004 Sep; 19(9):958-69. PubMed ID: 15304110 [TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Griffiths UK; Hutton G; Das Dores Pascoal E Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430 [TBL] [Abstract][Full Text] [Related]
4. Mathematical models of cervical cancer prevention in the Asia Pacific region. Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510 [TBL] [Abstract][Full Text] [Related]
6. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Hung HF; Chen TH Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755 [TBL] [Abstract][Full Text] [Related]
7. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Sarin SK; Kumar M; Eslam M; George J; Al Mahtab M; Akbar SMF; Jia J; Tian Q; Aggarwal R; Muljono DH; Omata M; Ooka Y; Han KH; Lee HW; Jafri W; Butt AS; Chong CH; Lim SG; Pwu RF; Chen DS Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):167-228. PubMed ID: 31852635 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ; Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149 [TBL] [Abstract][Full Text] [Related]
9. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. Aggarwal R; Ghoshal UC; Naik SR J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411 [TBL] [Abstract][Full Text] [Related]
10. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595 [TBL] [Abstract][Full Text] [Related]
11. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics. Jacobs RJ; Meyerhoff AS Sex Transm Dis; 2003 Nov; 30(11):859-65. PubMed ID: 14603096 [TBL] [Abstract][Full Text] [Related]
14. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis. Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424 [TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings. Dziekan G; Chisholm D; Johns B; Rovira J; Hutin YJ Bull World Health Organ; 2003; 81(4):277-85. PubMed ID: 12764494 [TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Dusheiko GM; Roberts JA Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389 [TBL] [Abstract][Full Text] [Related]
18. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management. Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251 [TBL] [Abstract][Full Text] [Related]